drugset / Trial / NCT03973918
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
Phase 2
Terminated
5 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collabPfizer · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.
Timeline
- Start
- 2019-07-29
- Primary completion
- 2022-04-30
- Completion
- 2023-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | 45 mg | — |
| Subject | Encorafenib | Small molecule | 450 mg | — |